(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1507900

自己マトリックス誘導軟骨形成（AMIC）の世界市場

Autologous Matrix-Induced Chondrogenesis (AMIC)

出版日
ページ情報
英文 214 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
自己マトリックス誘導軟骨形成（AMIC）の世界市場
出版日: 2024年07月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 214 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

自己マトリックス誘導軟骨形成（AMIC）の世界市場は2030年までに2億7,800万米ドルに達する見込み

2023年に1億6,440万米ドルと推定される自己マトリックス誘導軟骨形成（AMIC）の世界市場は、分析期間2023-2030年にCAGR 7.8%で成長し、2030年には2億7,800万米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるコラーゲンは、CAGR7.5%を記録し、分析期間終了時には1億5,880万米ドルに達すると予想されます。ヒアルロン酸セグメントの成長率は、分析期間中CAGR 6.9%と推定されます。

米国市場は5,280万米ドルと推定され、中国はCAGR 9.9％で成長すると予測されます。

米国の自己マトリックス誘導軟骨形成（AMIC）市場は、2023年に5,280万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 9.9%で推移し、2030年には2,610万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.4％と7.3％と予測されています。欧州では、ドイツがCAGR約8.1%で成長すると予測されています。

世界の自己マトリックス誘導軟骨形成（AMIC）市場- 主要動向と促進要因まとめ

自己マトリックス誘導軟骨形成（AMIC）は、関節の軟骨欠損を治療するために開発された革新的な手術法です。この手術法は、軟骨下骨に小さな穴を開けて血流と細胞移動を刺激するマイクロフラクチャー手術と、生体適合性コラーゲン膜の適用を組み合わせたものです。コラーゲン膜は、間葉系幹細胞から軟骨細胞への増殖と分化をサポートする足場となります。AMICは主に膝に使われるが、股関節、足首、肩など他の関節にも応用できます。この技術は、軟骨の損傷を修復し、痛みを軽減し、関節機能を改善することを目的としており、自己軟骨細胞移植（ACI）のような従来の軟骨修復法に代わる、侵襲の少ない方法を提供するものです。

AMICの手術は、まず関節鏡手術またはミニオープン手術で軟骨欠損部にアクセスします。損傷した軟骨を剥離した後、その下の骨に微小骨折を作り、幹細胞を豊富に含む骨髄要素を放出させる。その後、一般的にブタまたはウシ由来のコラーゲン膜を微小骨折部に被せ、フィブリン糊または縫合糸で固定します。この膜は、新しく形成される軟骨を保護する物理的なバリアとなるだけでなく、幹細胞が増殖・分化するのに最適な環境を作り出します。時間の経過とともに、これらの細胞は既存の軟骨と一体化した新しい軟骨組織を生成し、長期的な関節の健康を促進します。AMICは低侵襲であるため、侵襲性の高い手術に比べ、回復が早く、術後の不快感も少ないです。

自己マトリックス誘導軟骨形成（AMIC）市場の成長は、医療技術の進歩、関節損傷の有病率の増加、効果的な軟骨修復ソリューションの需要を反映したいくつかの要因によって牽引されています。重要な促進要因の1つは、スポーツ外傷や変形性関節症の罹患率の上昇であり、関節機能を回復させ痛みを緩和できる革新的な治療に対するニーズが高まっています。また、生体材料や手術手技の技術的進歩も、AMICの採用に寄与しています。このような進歩は、手技の有効性と信頼性を高めるからです。加えて、関節変性に罹患しやすい高齢化人口の増加も、軟骨修復療法に対する需要の増加につながっています。低侵襲手術技術へのシフトが市場の成長をさらに後押ししており、患者は回復に要する時間が短くリスクの少ない手術を求めています。また、さまざまな地域における規制当局の承認や有利な償還政策も、AMICの採用を後押ししています。これらの要因が総合的にAMIC市場の拡大と技術革新を促進し、臨床現場におけるAMICの継続的な進化と採用を確実なものにしています。

調査対象企業の例（注目の28社）

  • Anika Therapeutics, Inc.
  • Arthro Kinetics Biotechnology GmbH
  • B. Braun Melsungen
  • CONMED Corporation
  • Geistlich Pharma AG
  • JRI Orthopaedics Ltd.
  • Matricel GmbH
  • Vericel Corporation
  • Zimmer Biomet Holdings, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • ラテンアメリカ
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP10423

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market to Reach US$278.0 Million by 2030

The global market for Autologous Matrix-Induced Chondrogenesis (AMIC) estimated at US$164.4 Million in the year 2023, is expected to reach US$278.0 Million by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Collagen, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$158.8 Million by the end of the analysis period. Growth in the Hyaluronic Acid segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$52.8 Million While China is Forecast to Grow at 9.9% CAGR

The Autologous Matrix-Induced Chondrogenesis (AMIC) market in the U.S. is estimated at US$52.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$26.1 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market - Key Trends & Drivers Summarized

Autologous Matrix-Induced Chondrogenesis (AMIC) is an innovative surgical technique developed to treat articular cartilage defects in joints. This procedure combines microfracture surgery, which involves creating small holes in the subchondral bone to stimulate blood flow and cell migration, with the application of a biocompatible collagen membrane. The membrane serves as a scaffold to support the growth and differentiation of mesenchymal stem cells into chondrocytes, which are the cells responsible for producing cartilage. AMIC is primarily used in the knee, but it can also be applied to other joints such as the hip, ankle, and shoulder. This technique aims to repair cartilage damage, reduce pain, and improve joint function, offering a less invasive alternative to traditional cartilage repair methods like autologous chondrocyte implantation (ACI).

The procedure for AMIC begins with arthroscopic or mini-open surgery to access the cartilage defect. After debriding the damaged cartilage, microfractures are created in the underlying bone to release bone marrow elements rich in stem cells. A collagen membrane, typically derived from porcine or bovine sources, is then placed over the microfractured area and secured with fibrin glue or sutures. This membrane not only provides a physical barrier to protect the newly forming cartilage but also creates an optimal environment for the stem cells to proliferate and differentiate. Over time, these cells generate new cartilage tissue that integrates with the existing cartilage, promoting long-term joint health. The minimally invasive nature of AMIC allows for quicker recovery times and less postoperative discomfort compared to more invasive procedures.

The growth in the Autologous Matrix-Induced Chondrogenesis (AMIC) market is driven by several factors, reflecting advancements in medical technology, increasing prevalence of joint injuries, and the demand for effective cartilage repair solutions. One significant driver is the rising incidence of sports injuries and osteoarthritis, which has heightened the need for innovative treatments that can restore joint function and alleviate pain. Technological advancements in biomaterials and surgical techniques have also contributed to the adoption of AMIC, as these improvements enhance the effectiveness and reliability of the procedure. Additionally, the growing aging population, which is more susceptible to joint degeneration, has led to increased demand for cartilage repair therapies. The shift towards minimally invasive surgical techniques further supports the market growth, as patients seek procedures with shorter recovery times and lower risks. Regulatory approvals and favorable reimbursement policies in various regions are also encouraging the adoption of AMIC. These factors collectively drive the expansion and innovation in the AMIC market, ensuring its continued evolution and adoption in clinical practice.

Select Competitors (Total 28 Featured) -

  • Anika Therapeutics, Inc.
  • Arthro Kinetics Biotechnology GmbH
  • B. Braun Melsungen
  • CONMED Corporation
  • Geistlich Pharma AG
  • JRI Orthopaedics Ltd.
  • Matricel GmbH
  • Vericel Corporation
  • Zimmer Biomet Holdings, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Increasing Prevalence of Joint Disorders to Fuel Growth in Autologous Matrix-Induced Chondrogenesis Market
    • Autologous Matrix-Induced Chondrogenesis (AMIC): A Prelude
    • Global Economic Update
    • Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2017 through 2024
    • Global Inflation Rates (In %) for the Years 2019 through 2024
    • World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
    • Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • INFLUENCER/PRODUCT/TECHNOLOGY INSIGHTS
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AMIC Holds Significance in Cartilage Repair Domain
    • Rise in Sports Participation and Increase in Sports-Related Injuries Augment Growth Prospects
    • Autologous Matrix-Induced Chondrogenesis (AMIC) in Ankle Repair: A Review
    • Growing Demand for Minimally-Invasive Surgeries to Propel Market Growth
    • Rise in Incidence of Osteoporosis to Benefit Market Growth
    • Global Osteoporosis Prevalence: Number of People with Osteoporosis in Millions by Select Country/Region for 2012 and 2023
    • Cellular Therapy as Lifeblood of Clinical Routines Targeting Cartilage Regeneration
    • AMIC: Highly Effective in Management of Focal Chondral Defects of the Knee
    • Assessment of Open & Arthroscopic Approaches for AMIC to Repair Cartilage Defects
    • MACI Solutions: Promising Options in Articular Cartilage Treatment
    • Aging Population and their Vulnerability to Various Bone and Joint Related Diseases and Disorders Drive Healthy Market Growth
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Select Musculoskeletal Conditions - Percentage Breakdown by Age Group
    • Rise in Overweight Patients to Boost Prospects
    • Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Changing Lifestyle Impacting Bone Health
    • Rising Healthcare Spending Augurs Well for the Market
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Autologous Matrix-Induced Chondrogenesis (AMIC) Market Analysis of Annual Sales in US$ Thousand for Years 2017 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 4: World 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2017, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Collagen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Collagen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 7: World 13-Year Perspective for Collagen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hyaluronic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hyaluronic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 10: World 13-Year Perspective for Hyaluronic Acid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Polyethylene Glycol (PEG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Polyethylene Glycol (PEG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 13: World 13-Year Perspective for Polyethylene Glycol (PEG) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 16: World 13-Year Perspective for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 19: World 13-Year Perspective for Other Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 22: USA 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 25: Canada 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • JAPAN
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 28: Japan 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • CHINA
    • TABLE 29: China Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 31: China 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • EUROPE
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 34: Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2017, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 37: Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • FRANCE
    • TABLE 38: France Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 40: France 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • GERMANY
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 43: Germany 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 46: Italy 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • UNITED KINGDOM
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 49: UK 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 52: Spain 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 55: Russia 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • ASIA-PACIFIC
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • LATIN AMERICA
    • TABLE 62: Latin America Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Latin America Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 64: Latin America 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030
  • REST OF WORLD
    • TABLE 65: Rest of World Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of World Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2022 and % CAGR
    • TABLE 67: Rest of World 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2024 & 2030

IV. COMPETITION